Synthesis and assessment of [11C]acetylhomotaurine as an imaging agent for the study of the pharmacodynamic properties of acamprosate by positron emission tomography

Nuclear Medicine and Biology

Volumn 31, Issue 5, 2004, Pages 649-654

  Courtyn, Jan ^a   Cornelissen, Bart ^b   Oltenfreiter, Ruth ^b   Vandecapelle, Marleen ^b   Slegers, Guido ^b   Strijckmans, Karel ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

11C acetylhomotaurinate; Acamprosate; Alcohol addiction; Biodistribution; Carbon 11; PET

Indexed keywords

ACAMPROSATE; ACETIC ACID DERIVATIVE; ACETYLCHLORIDE C 11; ACETYLHOMOTAURINE C 11; CHLORINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CARBON; DIAGNOSTIC AGENT; DRUG DERIVATIVE; DRUGS USED IN THE TREATMENT OF ADDICTION; TAURINE;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD; BLOOD BRAIN BARRIER; BRAIN REGION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PURIFICATION; DRUG PURITY; DRUG SYNTHESIS; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RABBIT; RADIOACTIVITY; ALCOHOLISM; ANIMAL; BRAIN; CHEMISTRY; DRUG EFFECT; EVALUATION; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ALCOHOL DETERRENTS; ALCOHOLISM; ANIMALS; BRAIN; CARBON RADIOISOTOPES; HUMANS; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; MICE; POSITRON-EMISSION TOMOGRAPHY; RABBITS; RADIOPHARMACEUTICALS; TAURINE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 3042581225     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2003.11.001     Document Type: Article

References (34)

1. Boismare F., Daoust M., Moore N., Saligaut C., Lhuintre J.-P., Chrétien P., Durlach J. A homotaurine derivative reduces the voluntary intake of ethanol by rats - are cerebral GABA receptors involved? Pharmacol Biochem Behav. 21:1984;787-789
2. Spanagel R., Hölter S.M., Allingham K., Landgraf R., Zieglgänsberger W. Acamprosate and alcohol I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol. 305:1996;39-44
3. Spanagel R., Putzke J., Stefferl A., Schöbitz B., Zieglgänsberger W. Acamprosate and alcohol II. Effects on alcohol withdrawal in the rat. Eur J Pharmacol. 305:1996;45-50
4. Lhuintre J.-P., Daoust M., Moore N.D., Chrétien P., Saligaut C., Tran G., Boismare F., Hillemand B. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet. 8436:1985;1014-1016
5. Lhuintre J.-P., Moore N., Tran G., Steru L., Langrenon S., Daoust M., Parot P., Ladure P., Libert C., Boismare F., Hillemand B. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol. 25:1990;613-622
6. Paille F.M., Guelfi J.D., Perkins A.C., Royer R.J., Steru L., Parot P. Double-blind randomized multicenter trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 30:1995;239-247
7. Sass H., Soyka M., Mann K., Zieglgänsberger W. Relapse prevention by acamprosate - Results from a placebo-controlled study on alcohol dependence. Archiv Gen Psych. 53:1996;673-680
8. Pelc I., Verbanck P., Le Bon O., Gavrilovic M., Lion K., Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients, a 90-day placebo-controlled dose-finding study. Brit J Psych. 171:1997;73-77
9. Whitworth A.B., Fisher F., Lesch O.M., Nimmerrichter A., Oberbauer H., Platz T., Potgieter A., Walter H., Fleischhacker W.W. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 347:1996;1438-1442
10. Hoffman P.L., Tabakoff B. Alcohol dependence A commentary on mechanisms. Alcohol Alcohol. 31:1996;333-340
11. Danysz W., Dyr W., Jankowska E., Glazewski S., Kostowski W. The involvement of NMDA receptors in acute and chronic effects of ethanol. Alcohol Clin Exp Res. 16:1992;499-504
12. Littleton J., Little H. Current concepts of ethanol dependence. Addiction. 89:1994;1397-1412
13. Boismare F., Daoust M., Lhuintre J.P., Ladure P., Rinjard P. Are gamma aminobutyric acid-ergic receptors involved in the voluntary intake of ethanol by rats. J Pharmacol. 15:1984;457-458
14. Daoust M., Lhuintre J.-P., Saligaut C., Moore N., Chrétien P., Boismare F. Calcium bis acetyl homotaurine - a new GABAergic substance. J Pharmacol-Paris. 16:1985;108
15. Chabenat C., Chrétien P., Daoust M., Moore N., Andre D., Lhuintre J.-P., Saligaut C., Boucly P., Boismare F. Physiochemical, pharmacological and pharmacokinetic study of a new GABAergic compound, calcium acetylhomotaurinate. Methods Find Exp Clin Pharmacol. 10:1988;311-317
16. Daoust M., Legrand E., Gewiss M., Heidbreder C., De Witte P., Tran G., Durbin P. Acamprosate modulates synaptosomal GABA transmission in chronically alcoholized rats. Pharmacol Biochem Behav. 41:1992;669-674
17. Grant K.A., Woolverton W.L. Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals. Pharmacol Biochem Behav. 32:1989;607-611
18. Zieglgänsberger W., Hauser C., Putzke J., Spanagel R., Wetzel C. The enhanced excitability of central neurons following chronic alcohol intake is reduced by acamprosate. Alcohol Alcohol. 30:1995;552
19. B receptors in nucleus accumbens neurons. Alcohol Clin Exp Res. 22:1998;183-191
20. Zeise M.L., Kasparov S., Capogna M., Zieglgänsberger W. Acamprosate (calcium acetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex possible involvement of excitatory amino acid receptors. Eur J Pharmacol. 231:1993;47-52
21. Madamba S.G., Schweitzer P., Zieglgänsberger W., Siggins G.R. Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hyppocampal CA1 neurons in vitro. Alcohol Clin Exp Res. 20:1996;651-658
22. Naassila M., Hammoumi S., Legrand E., Durbin P., Daoust M. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate bindingsite in rat brain. Alcohol Clin Exp Res. 22:1998;802-809
23. al Qatari M., Bouchenafa O., Littleton J. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res. 22:1998;810-814
24. Dahchour A., De Witte P., Bolo N., Nédélic J.-F., Muzet M., Durbin P., Macher J.-P. Central effects of acamprosate Part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiat Res-Neuroim. 82:1998;107-114
25. Bolo N., Nd́élic J.-F., Muzet M., De Witte P., Dahchour A., Durbin P., Macher J.-P. Central effects of acamprosate Part 2. Acamprosate modifies the brain in-vivo proton magnetic resonance spectrum in healthy young male volunteers. Psychiat Res-Neuroim. 82:1998;115-127
26. st Campral-symposium ESBRA. Stuttgart, Germany: Springer, 1995, pp. 47-64
27. Dahchour A., De Witte P. Ethanol and amino acids in the central nervous system assessment of the pharmacological actions of acamprosate. Prog Neurobiol. 60:2000;343-362
28. Wilde M.I., Wagstaff A.J. Acamprosate a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs. 53:1997;1038-1053
29. Jones T. The role of positron emission tomography within the spectrum of medical imaging. Eur J Nucl Med. 23:1996;207-211
30. Comar D. PET for drug development and evaluation. 1995;Kluwer Academic Publishers, Dordrecht, The Netherlands
31. Courtyn J., Goethals P., Van der Eycken J., Dams R. Synthesis of C-11-labelled acamprosate for PET studies. J Labelled Compd Rad. 44:2001;643-651
32. 11C]acid chlorides as labelling agents. Appl Radiat Isot. 41:1990;471-476
33. Wilson A.A., Jin L., Garcia A., DaSilva J.N., Houle S. An admonition when measuring the lipophilicity of radiotracers using counting techniques. Appl Radiat Isot. 54:2001;203-208
34. Durbin P., Belleville M. Rat pharmacokinetic profile of acamprosate in plasma, brain and CSF. Alcohol Alcohol. 30:1995;548